Last reviewed · How we verify
NCT06291662
Evaluation of Performance Characteristics and Applicability in Oncology of Devices Customized Medical Devices Made by 3D Printing
NA trial testing 3D printer applications in Sarcoma in 12 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Kathleen McGreevy |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 12 |
| Start date | 1 January 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 3 locations across Italy |
Drugs / interventions tested
- 3D printer applications
Conditions studied
- Sarcoma — all drugs for Sarcoma →
- Intracranial Neoplasm — all drugs for Intracranial Neoplasm →
- Pelvic Bone Neoplasm — all drugs for Pelvic Bone Neoplasm →
Sponsor
Kathleen McGreevy
Who can join
Adults 7 to 70, any sex, with Sarcoma or Intracranial Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Technologies 3D are demonstrating enormous potential for innovation in the field of surgery,introducing the concept of "treatment customization" (from planning surgery to implant design and manufacturing) on the patient's anatomy, simply by taking advantage of the patient's own common diagnostic images and the flexibility of 3D printing. In fact, this new construction technology allows the construction of the complex anatomical geometries with economy, simplicity and on scales of production unattainable by other traditional technologies. This new construction technology allows, in fact, the construction of complex anatomical geometries with economy, simplicity and on scales of production unattainable by other traditional technologies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Next-generation epidermal patches: Bridging 3D and multidimensional printing for biomedical and personal care innovations.
El-Khordagui LK, El-Habashy SE, Simchi A, Tohamy HS, et al · · 2026 · PMID 42005999 · DOI 10.1016/j.bioactmat.2026.03.054
Verify or expand the search:
- PubMed search for NCT06291662
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoma
Currently open trials in the same condition.
- NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
- NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
- NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06291662 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kathleen McGreevy
- Last refreshed: 4 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06291662.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing